Impact of SARS-Cov-2 infection in patients with hypertrophic cardiomyopathy: results of an international multicentre registry.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Gimeno Juan R, Olivotto Iacopo, Rodríguez Ana Isabel, Ho Carolyn Y, Fernández Adrián, Quiroga Alejandro, Espinosa Mari Angeles, Gómez-González Cristina, Robledo María, Tojal-Sierra Lucas, Day Sharlene M, Owens Anjali, Barriales-Villa Roberto, Larrañaga Jose María, Rodríguez-Palomares Jose, González-Del-Hoyo Maribel, Piqueras-Flores Jesús, Reza Nosheen, Chumakova Olga, Ashley Euan A, Parikh Victoria, Wheeler Matthew, Jacoby Daniel, Pereira Alexandre C, Saberi Sara, Helms Adam S, Villacorta Eduardo, Gallego-Delgado María, de Castro Daniel, Domínguez Fernando, Ripoll-Vera Tomás, Zorio-Grima Esther, Sánchez-Martínez José Carlos, García-Álvarez Ana, Arbelo Elena, Mogollón María Victoria, Fuentes-Cañamero María Eugenia, Grande Elias, Peña Carlos, Monserrat Lorenzo, Lakdawala Neal K, Dilema International Cardiomyopathy and Heart Failure Registry and international SHaRe (Sarcomeric Human Cardiomyopathy Registry) Investigators group
Аннотация
METHODS AND RESULTS: Three hundred and five patients [age 56.6 ± 16.9 years old, 191 (62.6%) male patients] with HCM and SARS-Cov-2 infection were enrolled. The control group consisted of 91 131 infected individuals. Endpoints were (i) SARS-CoV-2 related mortality and (ii) severe clinical course [death or intensive care unit (ICU) admission]. New onset of atrial fibrillation, ventricular arrhythmias, shock, stroke, and cardiac arrest were also recorded. Sixty-nine (22.9%) HCM patients were hospitalized for non-ICU level care, and 21 (7.0%) required ICU care. Seventeen (5.6%) died: eight (2.6%) of respiratory failure, four (1.3%) of heart failure, two (0.7%) suddenly, and three (1.0%) due to other SARS-CoV-2-related complications. Covariates associated with mortality in the multivariable were age {odds ratio (OR) per 10 year increase 2.25 [95% confidence interval (CI): 1.12-4.51], P = 0.0229}, baseline New York Heart Association class [OR per one-unit increase 4.01 (95%CI: 1.75-9.20), P = 0.0011], presence of left ventricular outflow tract obstruction [OR 5.59 (95%CI: 1.16-26.92), P = 0.0317], and left ventricular systolic impairment [OR 7.72 (95%CI: 1.20-49.79), P = 0.0316]. Controlling for age and sex and comparing HCM patients with a community-based SARS-CoV-2 cohort, the presence of HCM was associated with a borderline significant increased risk of mortality OR 1.70 (95%CI: 0.98-2.91, P = 0.0600).
CONCLUSIONS: Over one-fourth of HCM patients infected with SARS-Cov-2 required hospitalization, including 6% in an ICU setting. Age and cardiac features related to HCM, including baseline functional class, left ventricular outflow tract obstruction, and systolic impairment, conveyed increased risk of mortality.